Faropenem: review of a new oral penem

• Published in: Expert review of anti-infective therapy Vol. 5; no. 2; pp. 185 - 198
• Main Authors: Schurek, Kristen N, Wiebe, Ryan, Karlowsky, James A, Rubinstein, Ethan, Hoban, Daryl J, Zhanel, George G
• Format: Journal Article
• Language: English
• Published: England Taylor & Francis 01.04.2007; Informa Healthcare
• Subjects: Administration, Oral; Animals; antibiotic; Bacterial Infections - drug therapy; Bacterial Infections - epidemiology; Bacterial Infections - metabolism; beta-Lactams - administration & dosage; beta-Lactams - chemistry; beta-Lactams - pharmacokinetics; carbapenem; faropenem; Humans; penem; β-lactam
• ISSN: 1478-7210; 1744-8336
• DOI: 10.1586/14787210.5.2.185

Faropenem medoxomil is a new orally administered penem antibiotic. Its chiral tetrahydrofuran substituent at position C2 is responsible for its improved chemical stability and reduced CNS effects, compared with imipenem. Faropenem demonstrates broad-spectrum in vitro antimicrobial activity against many Gram-positive and -negative aerobes and anaerobes, and is resistant to hydrolysis by nearly all β-lactamases, including extended-spectrum β-lactamases and AmpC β-lactamases. However, faropenem is not active against methicillin-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus faecium, Pseudomonas aeruginosa or Stenotrophomonas maltophilia. Prospective, multicenter, randomized, double-blind, comparative (not vs placebo) clinical trials of acute bacterial sinusitis (ABS), acute exacerbations of chronic bronchitis (AECB), community-acquired pneumonia (CAP) and uncomplicated skin and skin structure infections (uSSSIs) have demonstrated that faropenem medoxomil has equivalent efficacy and safety compared with cefuroxime, clarithromycin, azithromycin, amoxicillin, cefpodoxime and amoxicillin-clavulanate. The evidence supports faropenem medoxomil as a promising new oral β-lactam with proven efficacy and safety for the treatment of a variety of community-acquired infections. However, the US FDA recently rejected faropenem for all four indications stating that the clinical trials in ABS and AECB should have been performed versus a placebo. In the CAP studies, the FDA stated that they could not be certain of the validity of the study population actually having the disease and for uSSSI, the FDA stated that only a single trial was not adequate evidence of efficacy for this indication.